AJP - Heart AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 291: H1972-H1977, 2006. First published June 2, 2006; doi:10.1152/ajpheart.00043.2006
0363-6135/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/4/H1972    most recent
00043.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Z.
Right arrow Articles by Protter, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Z.
Right arrow Articles by Protter, A. A.

Selective inhibition of p38{alpha} MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury

Zhihe Li, Jing Ying Ma, Irene Kerr, Sarvajit Chakravarty, Sundeep Dugar, George Schreiner, and Andrew A. Protter

Department of Pharmacology, Scios Inc., Fremont, California

Submitted 10 January 2006 ; accepted in final form 26 May 2006

p38 MAPK is activated during heart diseases that might associate with myocardial damage and deterioration of cardiac function. In a rat model of myocardial injury, we have investigated cardioprotective effects of the inhibition of p38 MAPK using a novel, orally available p38{alpha} MAPK inhibitor. Rats were treated with N{omega}-nitro-L-arginine methyl ester (L-NAME, 40 mg·kg–1·day–1) in drinking water plus 1% salt for 14 days and ANG II (0.5 mg·kg–1·day–1) for 3 days. A selective p38{alpha} MAPK inhibitor, SD-282 (60 mg/kg), was administrated orally, twice a day for 4 days, starting 1 day before ANG II administration. The cardioprotective effects of p38{alpha} MAPK inhibition were evaluated by improvement of cardiac function, reduction of inflammatory cell infiltration, and cardiomyocyte apoptosis. SD-282 significantly improved cardiac function indicated by increasing stroke volume, cardiac output, ejection fraction, and stroke work and significantly decreasing arterial elastance. SD-282 also significantly reduced macrophage infiltration as judged by reduction of a specific marker, ED-1-positive staining cells (P < 0.05) in the myocardium. Furthermore, cardiomyocyte apoptosis as indicated by caspase-3 immunohistochemical staining was abolished by SD-282, and this effect may contribute to the reduction of myocardial damage evaluated by imaging analysis (P < 0.05 in both cases). Data suggest that p38{alpha} MAPK may play a critical role in the pathogenesis of cardiac dysfunction. Inhibition of p38{alpha} MAPK may be used as a novel cardioprotective strategy in attenuation of inflammatory response and deterioration of cardiac function that occurs in acute cardiovascular disease such as myocardial infarction.

p38 mitogen-activated protein kinase; remodeling



Address for reprint requests and other correspondence: Z. Li, Scios Inc., 6500 Paseo Padre Parkway, Fremont, CA 94555




This article has been cited by other articles:


Home page
Circ. Res.Home page
P. Krishnamurthy, J. Rajasingh, E. Lambers, G. Qin, D. W. Losordo, and R. Kishore
IL-10 Inhibits Inflammation and Attenuates Left Ventricular Remodeling After Myocardial Infarction via Activation of STAT3 and Suppression of HuR
Circ. Res., January 30, 2009; 104(2): e9 - e18.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Shinmura, K. Tamaki, and R. Bolli
Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2348 - H2355.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
L. Gu, V. Pandey, D. L. Geenen, S. A.K. Chowdhury, and M. R. Piano
Cigarette smoke-induced left ventricular remodelling is associated with activation of mitogen-activated protein kinases
Eur J Heart Fail, November 1, 2008; 10(11): 1057 - 1064.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
S. W. Rabkin and M. Y. C. Tsang
The action of nitric oxide to enhance cell survival in chick cardiomyocytes is mediated through a cGMP and ERK1/2 pathway while p38 mitogen-activated protein kinase-dependent pathways do not alter cell death
Exp Physiol, July 1, 2008; 93(7): 834 - 842.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
W. Chai, Y. Wu, G. Li, W. Cao, Z. Yang, and Z. Liu
Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury
Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E183 - E189.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. Mao, S. Fukuoka, C. Iwai, J. Liu, V. K. Sharma, S.-S. Sheu, M. Fu, and C.-s. Liang
Cardiomyocyte apoptosis in autoimmune cardiomyopathy: mediated via endoplasmic reticulum stress and exaggerated by norepinephrine
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1636 - H1645.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al.
Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice
Circulation, April 17, 2007; 115(15): 2022 - 2032.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.